[go: up one dir, main page]

AR109167A1 - Aumento de la fertilidad en especies bovinas - Google Patents

Aumento de la fertilidad en especies bovinas

Info

Publication number
AR109167A1
AR109167A1 ARP170102110A ARP170102110A AR109167A1 AR 109167 A1 AR109167 A1 AR 109167A1 AR P170102110 A ARP170102110 A AR P170102110A AR P170102110 A ARP170102110 A AR P170102110A AR 109167 A1 AR109167 A1 AR 109167A1
Authority
AR
Argentina
Prior art keywords
increase
cows
seq
nucleic acid
acid molecule
Prior art date
Application number
ARP170102110A
Other languages
English (en)
Inventor
Stuart Nibbelink
Leland Vickers
Terry Settje
Riekerink Richard Gerhardus Martinu Olde
Warren Tully
Daniel Keil
Jason Nickell
Albert Abraham
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of AR109167A1 publication Critical patent/AR109167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición inmunomoduladora donde la composición inmunomoduladora comprende: a) un vehículo de administración de liposomas catiónicos, y b) una molécula de ácido nucleico derivada de bacterias aisladas que no codifica para un inmunógeno para aumentar el porcentaje de concepción en vacas. Reivindicación 3: La composición inmunomoduladora de cualquiera de las reivindicaciones anteriores, donde la molécula de ácido nucleico tiene al menos un 80% de homología secuencial con la secuencia de ID SEC Nº 1, ID SEC Nº 2, o ID SEC Nº 3. Reivindicación 13: Un método para aumentar el porcentaje de concepción en vacas que comprende administrar a las vacas una cantidad eficaz de una composición de inmunomodulador, donde la composición del inmunomodulador comprende: a) un vehículo de administración de liposomas catiónicos, y b) una molécula de ácido nucleico derivada de bacterias aisladas que no codifican para un inmunógeno.
ARP170102110A 2016-07-26 2017-07-26 Aumento de la fertilidad en especies bovinas AR109167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
AR109167A1 true AR109167A1 (es) 2018-11-07

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102110A AR109167A1 (es) 2016-07-26 2017-07-26 Aumento de la fertilidad en especies bovinas

Country Status (22)

Country Link
US (1) US10933131B2 (es)
EP (1) EP3490598A1 (es)
JP (1) JP2019525935A (es)
KR (1) KR102473370B1 (es)
CN (1) CN109689095B (es)
AR (1) AR109167A1 (es)
AU (1) AU2017301528A1 (es)
BR (1) BR112019001599A2 (es)
CA (1) CA3031778A1 (es)
CL (1) CL2019000185A1 (es)
CO (1) CO2019000724A2 (es)
CR (1) CR20190037A (es)
DO (1) DOP2019000018A (es)
IL (1) IL264380A (es)
MX (1) MX386744B (es)
NZ (1) NZ750181A (es)
PE (1) PE20190566A1 (es)
PH (1) PH12019500191A1 (es)
SG (1) SG11201900710YA (es)
TW (1) TWI759317B (es)
UY (1) UY37346A (es)
WO (1) WO2018022583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CZ301488B6 (cs) * 1999-09-25 2010-03-24 University Of Iowa Research Foundation Použití imunostimulacních nukleových kyselin
EP1551221A4 (en) * 2002-07-03 2007-08-01 Coley Pharm Group Inc NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
CA2577270A1 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
MX336019B (es) 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
BR112013016231B1 (pt) 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2016207314A2 (en) 2015-06-26 2016-12-29 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
AU2016302436B2 (en) 2015-07-31 2022-03-03 Elanco Animal Health Gmbh Enhanced immune response in porcine species
EP3328423B1 (en) 2015-07-31 2021-05-26 Bayer Animal Health GmbH Enhanced immune response in fish

Also Published As

Publication number Publication date
IL264380A (en) 2019-02-28
TWI759317B (zh) 2022-04-01
TW201817427A (zh) 2018-05-16
CR20190037A (es) 2019-05-16
CL2019000185A1 (es) 2019-06-28
JP2019525935A (ja) 2019-09-12
KR20190032434A (ko) 2019-03-27
CA3031778A1 (en) 2018-02-01
PE20190566A1 (es) 2019-04-22
MX2019001126A (es) 2019-08-14
EP3490598A1 (en) 2019-06-05
DOP2019000018A (es) 2019-07-31
CO2019000724A2 (es) 2019-02-08
KR102473370B1 (ko) 2022-12-05
PH12019500191A1 (en) 2022-04-11
US10933131B2 (en) 2021-03-02
NZ750181A (en) 2023-02-24
CN109689095A (zh) 2019-04-26
SG11201900710YA (en) 2019-02-27
US20190388538A1 (en) 2019-12-26
UY37346A (es) 2018-02-28
AU2017301528A1 (en) 2019-02-14
WO2018022583A1 (en) 2018-02-01
MX386744B (es) 2025-03-19
BR112019001599A2 (pt) 2019-10-01
CN109689095B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
AR100238A1 (es) Método para producir l-aminoácidos en corinebacterias mediante el uso de un sistema de escisión de glicina
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
PE20190335A1 (es) Receptores de celulas t
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
MX2021001578A (es) Proteina asociada a crispr novedosa y uso de la misma.
BR112016016103A2 (pt) Composição de antígenos micobacterianos
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
ZA201704903B (en) Modified dnase and uses thereof
MX2016010794A (es) Proteina bioactiva, uso de esta y metodo para su produccion.
CL2020002373A1 (es) Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422).
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas
AR101146A1 (es) Proteína con actividad xilanasa
PH12017502323A1 (en) Novel xylanase
AR109167A1 (es) Aumento de la fertilidad en especies bovinas
MX2018002616A (es) Proteina de fusion.
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
MX376994B (es) Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis.
AR099811A1 (es) Microorganismos con una productividad de aminoácidos l mejorada y proceso para producir aminoácidos l
CN106687579A8 (zh) 产生二胺的微生物和使用该微生物产生二胺的方法
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
AR100954A1 (es) Proteína bioactiva, uso de ésta y método para su producción

Legal Events

Date Code Title Description
FB Suspension of granting procedure